FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386083949> ?p ?o ?g. }

• W4386083949 endingPage "904" @default.
• W4386083949 startingPage "904" @default.
• W4386083949 abstract "Trials showing equivalent or better outcomes with initial evaluation using coronary computed tomography angiography (cCTA) compared with stress testing in patients with stable chest pain have informed guidelines but raise questions about overtesting and excess catheterization.To test a modified initial cCTA strategy designed to improve clinical efficiency vs usual testing (UT).This was a pragmatic randomized clinical trial enrolling participants from December 3, 2018, to May 18, 2021, with a median of 11.8 months of follow-up. Patients from 65 North American and European sites with stable symptoms of suspected coronary artery disease (CAD) and no prior testing were randomly assigned 1:1 to precision strategy (PS) or UT.PS incorporated the Prospective Multicenter Imaging Study for the Evaluation of Chest Pain (PROMISE) minimal risk score to quantitatively select minimal-risk participants for deferred testing, assigning all others to cCTA with selective CT-derived fractional flow reserve (FFR-CT). UT included site-selected stress testing or catheterization. Site clinicians determined subsequent care.Outcomes were clinical efficiency (invasive catheterization without obstructive CAD) and safety (death or nonfatal myocardial infarction [MI]) combined into a composite primary end point. Secondary end points included safety components of the primary outcome and medication use.A total of 2103 participants (mean [SD] age, 58.4 [11.5] years; 1056 male [50.2%]) were included in the study, and 422 [20.1%] were classified as minimal risk. The primary end point occurred in 44 of 1057 participants (4.2%) in the PS group and in 118 of 1046 participants (11.3%) in the UT group (hazard ratio [HR], 0.35; 95% CI, 0.25-0.50). Clinical efficiency was higher with PS, with lower rates of catheterization without obstructive disease (27 [2.6%]) vs UT participants (107 [10.2%]; HR, 0.24; 95% CI, 0.16-0.36). The safety composite of death/MI was similar (HR, 1.52; 95% CI, 0.73-3.15). Death occurred in 5 individuals (0.5%) in the PS group vs 7 (0.7%) in the UT group (HR, 0.71; 95% CI, 0.23-2.23), and nonfatal MI occurred in 13 individuals (1.2%) in the PS group vs 5 (0.5%) in the UT group (HR, 2.65; 95% CI, 0.96-7.36). Use of lipid-lowering (450 of 900 [50.0%] vs 365 of 873 [41.8%]) and antiplatelet (321 of 900 [35.7%] vs 237 of 873 [27.1%]) medications at 1 year was higher in the PS group compared with the UT group (both P < .001).An initial diagnostic approach to stable chest pain starting with quantitative risk stratification and deferred testing for minimal-risk patients and cCTA with selective FFR-CT in all others increased clinical efficiency relative to UT at 1 year. Additional randomized clinical trials are needed to verify these findings, including safety.ClinicalTrials.gov Identifier: NCT03702244." @default.
• W4386083949 created "2023-08-24" @default.
• W4386083949 creator A5000568658 @default.
• W4386083949 creator A5004676254 @default.
• W4386083949 creator A5014777482 @default.
• W4386083949 creator A5016658327 @default.
• W4386083949 creator A5017152532 @default.
• W4386083949 creator A5023757786 @default.
• W4386083949 creator A5024589772 @default.
• W4386083949 creator A5026877561 @default.
• W4386083949 creator A5030616813 @default.
• W4386083949 creator A5035072694 @default.
• W4386083949 creator A5036625581 @default.
• W4386083949 creator A5043589105 @default.
• W4386083949 creator A5045551385 @default.
• W4386083949 creator A5046037086 @default.
• W4386083949 creator A5046257512 @default.
• W4386083949 creator A5046629853 @default.
• W4386083949 creator A5052190441 @default.
• W4386083949 creator A5057056663 @default.
• W4386083949 creator A5057932551 @default.
• W4386083949 creator A5062232887 @default.
• W4386083949 creator A5068838305 @default.
• W4386083949 creator A5070050361 @default.
• W4386083949 creator A5070387023 @default.
• W4386083949 creator A5071379214 @default.
• W4386083949 creator A5071968251 @default.
• W4386083949 creator A5079896280 @default.
• W4386083949 creator A5080222829 @default.
• W4386083949 creator A5081316775 @default.
• W4386083949 creator A5086795617 @default.
• W4386083949 creator A5089120659 @default.
• W4386083949 creator A5091313305 @default.
• W4386083949 date "2023-10-01" @default.
• W4386083949 modified "2023-10-13" @default.
• W4386083949 title "Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease" @default.
• W4386083949 cites W152096358 @default.
• W4386083949 cites W1938468392 @default.
• W4386083949 cites W2085309210 @default.
• W4386083949 cites W2105084079 @default.
• W4386083949 cites W2109647832 @default.
• W4386083949 cites W2160133249 @default.
• W4386083949 cites W2162782475 @default.
• W4386083949 cites W2165983414 @default.
• W4386083949 cites W2478342287 @default.
• W4386083949 cites W2531042121 @default.
• W4386083949 cites W2589094117 @default.
• W4386083949 cites W2625392805 @default.
• W4386083949 cites W2651185113 @default.
• W4386083949 cites W2755261156 @default.
• W4386083949 cites W2767629044 @default.
• W4386083949 cites W2888147975 @default.
• W4386083949 cites W2892274298 @default.
• W4386083949 cites W2920807567 @default.
• W4386083949 cites W2936006047 @default.
• W4386083949 cites W3001764054 @default.
• W4386083949 cites W3011371150 @default.
• W4386083949 cites W3089100520 @default.
• W4386083949 cites W3091323543 @default.
• W4386083949 cites W3165424262 @default.
• W4386083949 cites W3183084909 @default.
• W4386083949 cites W3209117858 @default.
• W4386083949 cites W4200199090 @default.
• W4386083949 cites W4225389575 @default.
• W4386083949 cites W4238277289 @default.
• W4386083949 cites W4280641978 @default.
• W4386083949 cites W4308369684 @default.
• W4386083949 cites W4323066973 @default.
• W4386083949 doi "https://doi.org/10.1001/jamacardio.2023.2595" @default.
• W4386083949 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37610731" @default.
• W4386083949 hasPublicationYear "2023" @default.
• W4386083949 type Work @default.
• W4386083949 citedByCount "3" @default.
• W4386083949 countsByYear W43860839492023 @default.
• W4386083949 crossrefType "journal-article" @default.
• W4386083949 hasAuthorship W4386083949A5000568658 @default.
• W4386083949 hasAuthorship W4386083949A5004676254 @default.
• W4386083949 hasAuthorship W4386083949A5014777482 @default.
• W4386083949 hasAuthorship W4386083949A5016658327 @default.
• W4386083949 hasAuthorship W4386083949A5017152532 @default.
• W4386083949 hasAuthorship W4386083949A5023757786 @default.
• W4386083949 hasAuthorship W4386083949A5024589772 @default.
• W4386083949 hasAuthorship W4386083949A5026877561 @default.
• W4386083949 hasAuthorship W4386083949A5030616813 @default.
• W4386083949 hasAuthorship W4386083949A5035072694 @default.
• W4386083949 hasAuthorship W4386083949A5036625581 @default.
• W4386083949 hasAuthorship W4386083949A5043589105 @default.
• W4386083949 hasAuthorship W4386083949A5045551385 @default.
• W4386083949 hasAuthorship W4386083949A5046037086 @default.
• W4386083949 hasAuthorship W4386083949A5046257512 @default.
• W4386083949 hasAuthorship W4386083949A5046629853 @default.
• W4386083949 hasAuthorship W4386083949A5052190441 @default.
• W4386083949 hasAuthorship W4386083949A5057056663 @default.
• W4386083949 hasAuthorship W4386083949A5057932551 @default.
• W4386083949 hasAuthorship W4386083949A5062232887 @default.
• W4386083949 hasAuthorship W4386083949A5068838305 @default.
• W4386083949 hasAuthorship W4386083949A5070050361 @default.
• W4386083949 hasAuthorship W4386083949A5070387023 @default.

• next